Participated · Equity · Aug 2026

Singular Photonics is an Edinburgh-based fabless semiconductor spinout from the University of Edinburgh built on research led by Professor Robert Henderson. The company develops image sensors based on single-photon avalanche diode (SPAD) technology that can detect and precisely time individual photons, enabling high-sensitivity and precise-timing imaging. Singular Photonics combines SPAD detectors with on-chip computation so data can be processed at the point of detection, reducing external data transfer and enabling real-time analysis. It currently offers two commercially available product families, Andarta and Sirona. The company's target application areas include machine vision, industrial automation, physical AI, scientific research and medical imaging. Recent financing of $2.15M is intended to expand engineering capacity and accelerate development and product introductions.

Participated · Seed · Apr 2026

Exergy3 develops ultra-high temperature thermal energy storage systems that convert surplus renewable electricity (including curtailed wind power) into high-temperature heat for industrial applications. The company is led by CEO Markus Rondé and is based in Edinburgh, Scotland. Following the £10M Seed raise, Exergy3 plans to scale manufacturing capacity and expand its team to support broader deployment at industrial sites. Its stated focus is turning excess renewable generation into usable energy rather than letting it go to waste. The company’s current financial update is the newly closed seed financing; no revenue or user metrics were reported in the article.

Participated · Series A · Mar 2026

Bioliberty develops Lifehub, an AI- and robotics-enabled platform that monitors functional recovery and enhances physical and occupational therapy delivery in post-acute settings. The company launched Lifehub Clinic in 2025 and is commercializing Lifehub in the U.S. while preparing Lifehub Home to extend therapy and monitoring into patients’ homes. Bioliberty reports growing adoption among major U.S. rehabilitation providers, including partnerships with one of the largest rehabilitation networks and Sheltering Arms Institute, and collaborates with research organizations such as Mount Sinai and the U.S. Department of Veterans Affairs. It holds multiple patents across its core technologies and states that Lifehub and Lifeglov are FDA-registered. Founded in 2023, the company has raised $17.5 million to date and is using recent proceeds to expand computer vision, care coordination features, and U.S. commercialization efforts.

Participated · Seed · Mar 2026

VerbaFlo provides a purpose-built AI communications layer for residential real estate, deploying specialised AI agents across leasing, marketing, operations, and maintenance and integrating with existing property systems. The platform centralises conversations across email, web chat, messaging apps, and phone to enable real-time, multilingual engagement at scale. VerbaFlo aims to improve response times, increase conversion rates, and reduce operational workload for property operators. The company currently supports more than 200,000 units globally and has grown across the UK and Europe with recent expansion into the United States. Founded in 2024, VerbaFlo plans further international rollouts and continued product development funded by its recent seed raise. Its commercial positioning emphasises vertical-specific AI automation rather than general chatbot solutions.

Participated · Equity · Mar 2026

BioCaptiva, a University of Edinburgh spin-out, has created the msX magnetic bead platform, which extracts circulating cell-free DNA directly from whole blood without centrifugation or extra reagents. By delivering higher-quality DNA with simpler, faster, and fully automatable workflows, the technology tackles a long-standing bottleneck in liquid biopsy sample preparation, a rapidly expanding segment of non-invasive cancer testing. The company recently launched msX research-use-only kits in Boston to generate supporting data across multiple oncology applications. New Chief Technology Officer Alan Schafer, who previously held senior roles at Inivata, Population Genetics Technologies, 14M Genomics, and GSK, has been hired to drive product and technology development. The fresh capital will fund continued R&D and the expansion of BioCaptiva’s product portfolio and applications. Financially, the company secured £1.58 million in its latest round, led by existing backer Archangels alongside several institutional investors, demonstrating ongoing investor confidence as BioCaptiva enters a key commercialization phase.